GeneDx Holdings Corp. is poised for strong Q3 results, driven by expanding exome and genome testing in pediatric and neonatal settings.Key metrics for WGS include test volume growth and reimbursement
Cidara’s CD388 is a novel flu prophylactic designed for universal prevention of seasonal and pandemic influenza through a single dose, with the potential to be the new standard of care.Phase
GeneDx delivered a strong Q2 2025, with revenues and earnings beating expectations and full-year guidance raised over 10%.Revenue growth is driven by higher testing volumes, improved reimbursement rates, and a
GeneDx delivered strong Q1 2025 results, beating revenue and EPS estimates, and raised full-year guidance.The test volume dip is attributable to seasonality, adverse weather, and one fewer business day, not
GeneDx Holdings Corp. leverages genomic sequencing and data science for early diagnosis and treatment, focusing on pediatric outpatient and neonatal ICU settings.GeneDx will report Q1 2025 earnings on April 30,
GeneDx Holdings Corp. leverages its genomic and data science expertise to provide precise medical diagnostics, focusing on rare diseases and pediatric exome/genome testing.The company’s second-quarter performance exceeded expectations, driven by
The S&P Healthcare Index rose 6% in the first half of the year, while the Prudent Healthcare model portfolio gained 25%.While the healthcare index underperformed the broader market, there are
Biotech indexes lagged broader market indexes in the first half of 2024, and trade at the same level as in early 2022.Biotech valuations are closely tied to the Fed's interest
Nuvalent, Inc. is a biotechnology company with precision-targeted treatments using kinase inhibitors for non-small cell lung cancer.NVL-520 targets ROS1-positive cancer and addresses treatment resistance, kinase mutations, and CNS-related adverse events,
GeneDx Holdings Corp. focuses on delivering precise medical diagnostic outcomes through its genomic expertise and rare disease dataset.Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) are key revenue drivers,
Biotech indexes, represented by IBB and XBI, have been facing pressure since March and trading at valuations seen in April 2020.The key factor influencing biotech valuations, discussed below, is expected
The healthcare sector had a flat performance in 2023 due to unique issues.Drug price regulation will be an uphill challenge for the sector this year.Defensive healthcare industry groups should do
The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield.In 2024, the 10-year yield should favorably support biotech stocks.Promising advancements in weight loss drugs,
Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market.The direction of the 10-year
Akero Therapeutics is making strong progress in developing a treatment for NASH, an area of high unmet medical need.The company's lead product candidate has shown promising and highly significant results
Iveric bio, Inc., focused on developing treatments for retinal diseases, has announced its acquisition by Astellas Pharma Inc.Iveric bio, Inc. stock trades at a discount of over 5% for an
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity.Biotech deal-making has been increasing,
The collapse of Silicon Valley Bank led to a market-wide selloff and caused significant volatility in biotech and technology stocks.Regulators are expected to take swift action this week to contain
Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500.When the end to restrictive policy is in sight, then the sector is likely to
Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half.Biotechnology should be favorably positioned relative to the market if the economy
